Mark B. Leick

3.5k citations

47 papers · 1.8k indexed · 3 hit papers · h-index 16

Impact in

Oncology top 2%
- CAR-T cell therapy research
Immunology top 5%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses

Papers in ⓘ

Oncology 35
- CAR-T cell therapy research 34
Molecular Biology 13
- CRISPR and Genetic Engineering 7
- Viral Infectious Diseases and Gene Expression in Insects 4

Co-authors: Marcela V. Maus (38 shared papers)Matthew J. Frigault (16 shared papers)Bryan D. Choi (10 shared papers)Rebecca C. Larson (16 shared papers)Amanda A. Bouffard (18 shared papers)Stefanie R. Bailey (10 shared papers)Bob S. Carter (3 shared papers)Irene Scarfò (10 shared papers)
Journals: Blood (9 papers)Cancer Research (5 papers)Journal for ImmunoTherapy of Cancer (5 papers)New England Journal of Medicine (3 papers)Molecular Therapy (2 papers)
Partner nations: United States United Kingdom Netherlands

In The Last Decade

Mark B. Leick

41 papers receiving 1.8k citations

Hit Papers

align trajectories log scale

Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma 2024 · 210 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2024 New England Journal of Medicine
2022 Nature
2019 Nature Biotechnology

Peers

Countries citing papers authored by Mark B. Leick

Since Specialization

Citations

This map shows the geographic impact of Mark B. Leick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark B. Leick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark B. Leick more than expected).

Fields of papers citing papers by Mark B. Leick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark B. Leick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark B. Leick. The network helps show where Mark B. Leick may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark B. Leick, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark B. Leick Line = papers co-authored together Mark B. Leick links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 47 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity Nature Biotechnology ·Bryan D. Choi, Xiaoling Yu, Ana P. Castaño, Amanda A. Bouffard, Andrea Schmidts, Rebecca C. Larson, Stefanie R. Bailey, Angela C. Boroughs, Matthew J. Frigault, Mark B. Leick, Irene Scarfò, Curtis L. Cetrulo, Shadmehr Demehri, Brian V. Nahed, Daniel P. Cahill, Hiroaki Wakimoto, William T. Curry, Bob S. Carter, Marcela V. Maus Hit paper breakdown →	2019	426
2	CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma Journal for ImmunoTherapy of Cancer ·Bryan D. Choi, Xiaoling Yu, Ana P. Castaño, Henia Darr, Daniel B. Henderson, Amanda A. Bouffard, Rebecca C. Larson, Irene Scarfò, Stefanie R. Bailey, Genevieve M. Gerhard, Matthew J. Frigault, Mark B. Leick, Andrea Schmidts, Jason Sagert, William T. Curry, Bob S. Carter, Marcela V. Maus	2019	228
3	CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours Nature ·Rebecca C. Larson, Michael C. Kann, Stefanie R. Bailey, Nicholas J. Haradhvala, Paula Montero Llopis, Amanda A. Bouffard, Irene Scarfò, Mark B. Leick, Korneel Grauwet, Trisha R. Berger, Kai Stewart, Praju Vikas Anekal, Max Jan, Julia Joung, Andrea Schmidts, Tamara Ouspenskaia, Travis Law, Aviv Regev, Gad Getz, Marcela V. Maus Hit paper breakdown →	2022	225
4	Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma New England Journal of Medicine ·Bryan D. Choi, Elizabeth R. Gerstner, Matthew J. Frigault, Mark B. Leick, Christopher Mount, Leonora Balaj, Sarah Nikiforow, Bob S. Carter, William T. Curry, Kathleen Gallagher, Marcela V. Maus Hit paper breakdown →	2024	210
5	Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma Blood ·Matthew J. Frigault, Jörg Dietrich, María Martínez-Lage, Mark B. Leick, Bryan D. Choi, Zachariah DeFilipp, Yi‐Bin Chen, Jeremy S. Abramson, Jennifer L. Crombie, Philippe Armand, Lakshmi Nayak, Chris Panzini, Lauren S. Riley, Kathleen Gallagher, Marcela V. Maus	2019	160
6	Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia Cancer Cell ·Mark B. Leick, Harrison Silva, Irene Scarfò, Rebecca C. Larson, Bryan D. Choi, Amanda A. Bouffard, Kathleen Gallagher, Andrea Schmidts, Stefanie R. Bailey, Michael C. Kann, Max Jan, Marc Wehrli, Korneel Grauwet, Nora Horick, Matthew J. Frigault, Marcela V. Maus	2022	88
7	Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS) Journal for ImmunoTherapy of Cancer ·Marc Wehrli, Kathleen Gallagher, Yi‐Bin Chen, Mark B. Leick, Steven L. McAfee, Areej El‐Jawahri, Zachariah DeFilipp, Nora Horick, Paul V. O’Donnell, Thomas R. Spitzer, Bimal Dey, Daniella Cook, Michael Trailor, Kevin Lindell, Marcela V. Maus, Matthew J. Frigault	2022	80
8	Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy Blood Advances ·Peter G. Miller, Adam S. Sperling, Elliott J. Brea, Mark B. Leick, Geoffrey Fell, Max Jan, Satyen H. Gohil, Yu‐Tzu Tai, Nikhil C. Munshi, Catherine J. Wu, Donna Neuberg, Marcela V. Maus, Caron A. Jacobson, Christopher J. Gibson, Benjamin L. Ebert	2021	67
9	Loss of imprinting of IGF2 and the epigenetic progenitor model of cancer. PubMed ·Mark B. Leick, Christopher Shoff, Erwin Wang, Jaclyn L Congress, G. Ian Gallicano	2012	36
10	The Future of Targeting FLT3 Activation in AML Current Hematologic Malignancy Reports ·Mark B. Leick, Mark J. Levis	2017	33
11	Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicity Blood ·Charlotte Graham, Won‐Ho Lee, Hadley R. Wiggin, Valentina M. Supper, Mark B. Leick, Filippo Birocchi, Andrew J. Yee, Angelina Petrichenko, J.K. Everett, Frederic D. Bushman, Hossein Sadrzadeh, Otto Rapalino, Daniel Chiu, Isabel Arrillaga‐Romany, Marcela V. Maus, Matthew J. Frigault, Kathleen Gallagher	2023	32
12	Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies Molecular Therapy ·Mark B. Leick, Marcela V. Maus, Matthew J. Frigault	2020	22
13	Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia Molecular Therapy — Oncolytics ·Justin C. Boucher, Bishwas Shrestha, Paresh Vishwasrao, Mark B. Leick, Estelle V. Cervantes, Tayyebb Ghafoor, Kayla Reid, Kristen Spitler, Bin Yu, Brian C. Betts, José A. Guevara-Patiño, Marcela V. Maus, Marco L. Davila	2023	21
14	Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources Journal for ImmunoTherapy of Cancer ·Andrea Schmidts, Leah C Marsh, Ambike Aarti Srivastava, Amanda A. Bouffard, Angela C. Boroughs, Irene Scarfò, Rebecca C. Larson, Felipe Bedoya, Bryan D. Choi, Matthew J. Frigault, Stefanie R. Bailey, Mark B. Leick, Sonika Vatsa, Michael C. Kann, Michelle S. Prew, Benjamin P. Kleinstiver, J. Keith Joung, Marcela V. Maus	2020	18
15	T Cell Clonal Dynamics Determined by High-Resolution TCR-β Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation ·Mark B. Leick, Rachel M. Gittelman, Erik Yusko, Catherine Sanders, Harlan Robins, Zachariah DeFilipp, Sarah Nikiforow, Jerome Ritz, Yi‐Bin Chen	2020	15
16	Toxicities associated with immunotherapies for hematologic malignancies Best Practice & Research Clinical Haematology ·Mark B. Leick, Marcela V. Maus	2018	15
17	Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics Science Translational Medicine ·Felix Korell, Michael Olson, Diego Salas‐Benito, Mark B. Leick, Rebecca C. Larson, Amanda A. Bouffard, Harrison Silva, Alessandro Gasparetto, Trisha R. Berger, Michael C. Kann, Markus Mergen, Tamina Kienka, Marc Wehrli, Nicholas J. Haradhvala, Stefanie R. Bailey, Anthony Letai, Marcela V. Maus	2024	14
18	Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver Cancer Chemotherapy and Pharmacology ·Apostolia M. Tsimberidou, Mark B. Leick, JoAnn Lim, Siqing Fu, Jennifer J. Wheler, Sarina A. Piha‐Paul, David S. Hong, Gerald S. Falchook, Aung Naing, Ishwaria M. Subbiah, Adoneca Fortier, Rony Avritscher, Razelle Kurzrock	2012	13
19	CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML Blood ·Harrison Silva, Grace Martin, Filippo Birocchi, Marc Wehrli, Michael C. Kann, Valentina M. Supper, Aiyana Parker, Charlotte Graham, Alexandra Bratt, Amanda A. Bouffard, Hannah Donner, Giulia Escobar, H. TAKEI, Alexander Armstrong, S Goncalves, Trisha R. Berger, Bryan D. Choi, Marcela V. Maus, Mark B. Leick	2024	11
20	Stealth transgenes enable CAR-T cells to evade host immune responses Journal for ImmunoTherapy of Cancer ·Korneel Grauwet, Trisha R. Berger, Michael C. Kann, Harrison Silva, Rebecca C. Larson, Mark B. Leick, Stefanie R. Bailey, Amanda A. Bouffard, David G. Millar, Kathleen Gallagher, Cameron J. Turtle, Matthew J. Frigault, Marcela V. Maus	2024	8

About Mark B. Leick

Mark B. Leick is a scholar working on Oncology, Molecular Biology, Immunology, Biomedical Engineering and Hematology, having authored 47 papers that have together received 1.8k indexed citations. Recurring topics across this work include CAR-T cell therapy research (34 papers), Nanowire Synthesis and Applications (8 papers), CRISPR and Genetic Engineering (7 papers), Immune Cell Function and Interaction (7 papers), Virus-based gene therapy research (5 papers), T-cell and B-cell Immunology (4 papers), Advancements in Semiconductor Devices and Circuit Design (4 papers) and Viral Infectious Diseases and Gene Expression in Insects (4 papers). The work is most often cited by research in Oncology (1.4k citations), Immunology (518 citations), Genetics (217 citations), Genetics (408 citations) and Hematology (135 citations). Mark B. Leick has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Marcela V. Maus, Matthew J. Frigault, Bryan D. Choi, Rebecca C. Larson, Amanda A. Bouffard, Stefanie R. Bailey, Bob S. Carter, Irene Scarfò, William T. Curry and Andrea Schmidts. Their work appears in journals such as Blood, Cancer Research, Journal for ImmunoTherapy of Cancer, New England Journal of Medicine and Molecular Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact